MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

The majority of patients with newly diagnosed chronic myeloid leukemia (CML) will enjoy a life expectancy equivalent to that of unaffected individuals, but will remain on life-long treatment with a concomitant requirement for on-going hospital interactions for molecular monitoring and drug dispensin...

Descripción completa

Detalles Bibliográficos
Autores principales: Claudiani, Simone, Gatenby, Aoife, Szydlo, Richard, Nesr, George, Abulafia, Adi Shacham, Palanicawandar, Renuka, Nteliopoulos, Georgios, Khorashad, Jamshid, Foroni, Letizia, Apperley, Jane F., Milojkovic, Dragana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821602/
https://www.ncbi.nlm.nih.gov/pubmed/30923102
http://dx.doi.org/10.3324/haematol.2018.214809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821602/
https://www.ncbi.nlm.nih.gov/pubmed/30923102
http://dx.doi.org/10.3324/haematol.2018.214809

Ejemplares similares